Hajra Nashin

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its strategic collaboration and license agreement with Roche. Lawyers Ken Krisko, Marya Postner, Bin Wang, Hajra Nashin and Brendan Haberle led the Cooley team advising Poseida. 

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Cooley advised Nykode Therapeutics in its license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases. 

Under the terms of the agreement, Nykode Therapeutics will receive a $30 million upfront payment and a $20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than $875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than $925 million, plus royalties.

Lawyers Ken Krisko, Christophe Beauduin, John Forrest, Marya Postner and Hajra Nashin led the Cooley team advising Nykode.